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AbstrACt
background Early onset eczema is associated with 
food allergy, and allergic reactions to foods can cause 
acute exacerbations of eczema. Parents often pursue 
dietary restrictions as a way of managing eczema and 
seek allergy testing for their children to guide dietary 
management. However, it is unclear whether test-guided 
dietary management improves eczema symptoms, and 
whether the practice causes harm through reduced 
use of conventional eczema treatment or unnecessary 
dietary restrictions. The aim of the Trial of Eczema allergy 
Screening Tests Study is to determine the feasibility of 
conducting a trial comparing food allergy testing and 
dietary advice versus usual care, for the management of 
eczema in children.
Methods and analysis Design: A single centre, two-
group, individually randomised, feasibility randomised 
controlled trial (RCT) with economic scoping and a nested 
qualitative study. Setting: General Practioner (GP) surgeries 
in the west of England. Participants: children aged over 3 
months and less than 5 years with mild to severe eczema. 
Interventions: allergy testing (structured allergy history and 
skin prick tests) or usual care. Sample size and outcome 
measures: we aim to recruit 80 participants and follow 
them up using 4-weekly questionnaires for 24 weeks. 
Nested qualitative study: We will conduct ~20 interviews 
with parents of participating children, 5–8 interviews with 
parents who decline or withdraw from the trial and ~10 
interviews with participating GPs. Economic scoping: We 
will gather data on key costs and outcomes to assess the 
feasibility of carrying out a cost-effectiveness analysis in a 
future definitive trial.
Ethics and dissemination The study has been reviewed 
by the Health Research Authority and given a favourable 
opinion by the NHS REC (West Midlands – South 
Birmingham Research Ethics Committee, Reference 
Number 18/WM/0124). Findings will be submitted for 
presentation at conferences and written up for publication 
in peer-reviewed journals, which may include mixed-
method triangulation and integration of the quantitative 
and qualitative findings. 
trial registration ISRCTN15397185; Pre-results.
IntroduCtIon
background and rationale
Childhood eczema is a common long-term 
condition characterised by dry and itchy skin. 
In accordance with the recommended nomen-
clature of the World Allergy Organisation, we 
use the label ‘eczema’ to refer to the clinical 
phenotype of atopic eczema/dermatitis.1 
strength and limitations
 ► This is the first randomised controlled trial exploring 
test-guided dietary management for treating ecze-
ma to be done in a primary care setting, where most 
children with eczema are diagnosed and managed 
in the UK.
 ► Data on the processes and outcomes that are be-
ing collected will help determine the feasibility of a 
definitive trial and associated economic evaluation.
 ► The nested qualitative study will help to interpret 
and explain the quantitative feasibility findings and 
to generate new knowledge around the issues of 
food allergy, allergy tests and dietary modification in 
children with eczema, from the perspective of par-
ents and GPs.
 ► The study is being conducted in a single centre in 
the west of England, which may limit the generalis-
ability of the findings.
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Eczema affects around 20% of preschool age children; 
60% of these develop symptoms in the first year of life and 
90% by 5 years of age.2 In the UK most children with eczema 
are diagnosed and managed in primary care with a combi-
nation of emollients and topical corticosteroids. Having 
eczema can significantly impact the quality of life of the 
affected child and their family. Treatment adherence can 
be problematic for numerous reasons, including parents/
carers (hereafter, ‘parents’) seeking a ‘cure’ through dietary 
exclusions for possible food allergy rather than ‘control’ 
through long-term use of topical treatments.3–5
Eczema is associated with food allergy, especially 
early onset, troublesome eczema,6 and parents of children 
with eczema often try dietary exclusions in an attempt to 
reduce symptom severity and may seek allergy testing to 
guide such dietary exclusions. Allergic reactions to food can 
cause an acute exacerbation of eczema, either as part of an 
IgE-mediated reaction or as an isolated non-IgE mediated 
reaction to a food (see box 1). Parents’ suspicions of food 
allergies in general and especially with respect to eczema 
have low specificity. Depending on the specific population 
studied and the definitions used, 15%–36% of children with 
eczema compared with about 6% of the general population 
have a food sensitivity (a ‘positive’ test result, without clinical 
symptoms) or allergy.7 Clinical practice in offering allergy 
tests to parents of children with eczema varies significantly, 
with many allergy clinics routinely ‘screening’ for associated 
food allergies, but few primary care services offering testing 
in the absence of a history suggesting an IgE-mediated reac-
tion to a food.
A Cochrane review8 of dietary exclusions for adults and 
children with eczema published in 2008 did not find any 
evidence of benefit for exclusion diets in unselected popu-
lations (ie, those without clinically suspected food allergies), 
but did identify one trial which suggested that infants with 
suspected egg allergy who have positive specific IgE to eggs 
may benefit from an egg-free diet.9 While this suggests 
that test-guided dietary management may be worthwhile, 
both this and two other subsequently published systematic 
reviews10 11 have called for better-designed and conducted 
trials. We have not identified any economic evaluations 
in this area and while concerns about food allergy have 
been raised during in-depth interviews of parents’ general 
experiences of looking after children with eczema,3–5 and 
have arisen as an important concern for parents in online 
discussion forums,12 we are not aware of any qualitative work 
specifically exploring this issue.
Aim and objectives
The aim of the study to determine the feasibility of 
conducting a trial comparing test-guided dietary manage-
ment versus usual care, for the management of eczema 
in children.
The objectives are to explore the following factors 
that will determine the feasibility and inform the design 
of a future, full-scale clinical and cost-effectiveness 
randomised controlled trial (RCT):
 ► Participant recruitment (including numbers poten-
tially eligible), retention and adherence to alloca-
tion/dietary advice.
 ► Outcome completion rates.
 ► Logistics of trial processes and their acceptability to 
participants.
trial design
The Trial of Eczema allergy Screening Tests (TEST) is a 
single-centre, two-group, individually randomised, feasibility 
RCT13 with economic scoping and nested qualitative study.
MEthods And AnAlysIs
study setting
Primary care (GP surgeries) in the west of England.
recruitment
The stages of participant recruitment are shown in 
figure 1.
We will identify children aged between 3 months and 5 
years with eczema via an electronic query-based records 
search developed by the research team and run by practice 
staff at the GP surgeries. A GP or a delegated member of the 
practice team will screen the search results for inclusion/
exclusion criteria and any other known adverse medical 
or social circumstances that would make invitation to the 
study inappropriate. Surgeries will be asked to provide the 
research team with the number of participants excluded, 
along with a brief reason for exclusion. Parents of potentially 
eligible children will be sent an invitation pack, comprising 
an invitation letter, study flyer and response to the invitation 
to participate form. In addition, we will also recruit partic-
ipants opportunistically, by placing posters in participating 
GP surgeries and supplying study flyers for practice staff and 
health visitors to hand out.
Interested families will be asked to complete a brief 
screening questionnaire that the research team will use 
to assess initial eligibility. Parents of potentially eligible 
participants will be contacted by a member of the research 
team to explain more about the study and schedule a 
baseline assessment at a participating GP surgery. At this 
box 1 IgE-mediated and non-IgE-mediated food allergy
 ► The World Allergy Organisation defines food allergy as an im-
mune-mediated hypersensitivity reaction to food and may be divid-
ed into IgE-mediated and non-IgE-mediated reactions.1
 ► IgE-mediated food allergy involves immediate hypersensitivity 
(typically within 5–30 min of ingestion and always within 2 hours) 
through the action of mast cells. It can be reliably diagnosed when 
there is a typical history of reaction within 1–2 hours of exposure 
and demonstration of specific IgE to the relevant food on blood or 
skin prick testing.
 ► Non-IgE-mediated food allergy is delayed (between 2–48 hours 
postingestion) and thought to be caused by an aberrant T cell re-
sponse. It is more difficult to diagnose as there are no reliable di-
agnostic tests other than dietary exclusions and re-introduction.47
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visit, consent will be received, baseline data collected and 
randomisation undertaken.
Eligibility and allocation
Inclusion and exclusion criteria are summarised in box 2.
Individuals will be randomised to intervention or 
comparator groups (1:1 ratio), stratified by age (less 
than 1 year, 1 year to less than 2 years, 2 years and above) 
and eczema severity (mild, moderate/severe)14 and 
blocked within strata, using the Bristol Randomised Trials 
Figure 1 Overview of participant pathway through the study. EASI, Eczema Area Severity Index; GP, general practitioner; PN, 
practice nurse; POEM, Patient Oriented Eczema Measure; SAH, structured allergy history; SPT, skin prick test. 
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Collaboration web-based system. Allocation concealment 
will be ensured, as the clinical studies officer (CSO) will 
not randomise the participant until all baseline measure-
ments have been completed.
Interventions
All participants allocated to the intervention group will 
undergo a structured allergy history, skin prick tests 
(SPTs) and will be given dietary advice. Where the child’s 
history and the results of the SPT results are equivocal, 
participants will be offered repeat SPTs and/or oral food 
challenges (OFCs) and/or home dietary trial of exclu-
sion or inclusion. Repeat SPTs will be done either at the 
same appointment or 12 weeks after the baseline appoint-
ment. Advice will be tailored accordingly for mothers who 
are breast feeding and/or babies who have not yet been 
weaned.
 ► Structured allergy history: The researcher (CSO) will 
first take a structured allergy history. There are recom-
mendations for what a structured allergy history 
should comprise,15 but no validated questionnaires. 
With reference to published guidance,7 16 we have 
therefore modified questionnaires developed for the 
Barrier Enhancement for Eczema Prevention (BEEP) 
Trial.17 These questions capture relevant symptoms 
(skin, respiratory and gastrointestinal) and timing of 
onset in relation to ingestion of the study foods.
 ► SPTs: The CSO will carry out the SPTs using 
commercial extracts of cow's milk, hen's egg (white), 
wheat, peanut, cashew and codfish, along with posi-
tive (1.0% histamine) and negative (0.9% saline) 
controls.18 19One millimetre shouldered sterile 
lancets will be used (ALK, Denmark) and the diam-
eter (mean of longest and shortest perpendicular axis 
if ovoid or irregular) of any weal reaction, resulting 
from the release of histamine and other mediators, 
will be measured after 15 min.20
 ► OFC: Supervised open food challenges will be under-
taken at Bristol Royal Children’s Hospital, using 
a modified Practical Allergy (PRACTALL) dosing 
schedule and criteria for interpretation of challenge 
outcome,21 usually within 1–2 weeks of the baseline 
appointment. Consent specifically for OFC will be 
received and standard hospital protocols for each 
allergen will be followed. For pragmatic and cost 
reasons, they will be unblinded as in normal clinical 
practice, rather than the diagnostic ‘gold standard’ of 
the double-blind, placebo-controlled food challenge.22
 ► Home dietary trial: For participants whose history 
and investigation findings suggest the possibility of 
a delayed-type reaction, they will be advised to either 
exclude or reintroduce (as appropriate to their path 
in the study) the possible allergen from/into their 
diet over a period of 2–4 weeks, as per current clinical 
practice.16
 ► Dietary advice: An algorithm describing the approach 
to the interpretation of the structured allergy history, 
SPT results, ±OFC, and consequent dietary guidance, 
will be developed and tested as part of this feasibility 
study, guided in part by published guidance on diag-
nosis of food allergy in epidemiological studies.23 All 
participants’ results will also be reviewed by an expert 
allergy panel and dietary advice relayed to their family 
accordingly.
Participants in the comparator group will receive care 
as usual, as described in the National Institute for Health 
and Care Excellence (NICE) eczema and allergy in chil-
dren guidelines and will not receive any additional assess-
ments or tests.16 24 Any allergy tests and subsequent advice 
will be monitored as part of this feasibility study.
Regardless of allocation, all care after randomisation, 
including investigations and/or referrals for possible 
food allergies, will remain with the participant’s GP.
outcomes
The primary outcome is the feasibility of conducting 
the trial (recruitment, retention, contamination) and 
collecting the required data (online supplementary 
appendix 1). A complete schedule of data collection can 
be found in table 1. The feasibility of collecting data in 
the key domains that are likely to be used in the defin-
itive trial (symptoms, clinical signs, long-term control 
and quality of life, as recommended by the core outcome 
group for eczema, HOME)25 will be assessed:
 ► Patient Oriented Eczema Measure26 (POEM, proposed 
primary outcome in the definitive trial) completed 
by proxy (parent report) captures symptoms of 
importance to parents and patients.27 Emerging data 
suggest that monthly, as opposed to weekly, collection 
is adequate for the purpose of capturing long-term 
control.28 It demonstrates good validity, repeatability 
and responsiveness to change.29 30
 ► Eczema Area Severity Index (EASI),31 a validated 
scoring system that grades the physical signs of eczema. 
Administered by a trained researcher, it will provide 
an independent assessment of eczema severity.
 ► Long-term control will be captured by repeated, 
4 weekly, administration of POEM.
box 2 Participant eligibility criteria
Inclusion criteria are:
 ► Child aged between 3 months and 5 years with eczema diagnosed 
by an appropriately qualified healthcare professional (registered 
doctor, nurse or health visitor).
 ► Patient Oriented Eczema Measure Score of >2.
 ► Consent given by a person with parental responsibility for the 
participant.
Exclusion criteria are:
 ► Child with medically diagnosed food allergy, awaiting referral/inves-
tigations for possible food allergy or had previous investigations for 
food allergy (not including home testing).
 ► The person responsible for consent has insufficient written English 
to complete the outcome measures, or has another child already 
taking part in the trial.
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 ► Disease-specific (Atopic Dermatitis Quality of Life, 
ADQoL;32 Infant Dermatitis Quality of Life33 34 and 
generic (Children’s Health Utility 9D, CHU-9D35 36 
quality of life measures will be collected at baseline, 
week 8 and week 24. The CHU-9D is currently vali-
dated for children aged 7 years and over,37 so addi-
tional guidance notes and validation questions are 
included.
With consent, participants’ electronic medical records 
(EMRs) will be reviewed at 24 weeks (from 4 weeks before 
and for the duration of time in the study) for data on 
NHS consultations, treatments, referrals for eczema/
allergies and relevant prescribed medications.
For participants in the intervention group, the following 
data will also be collected:
 ► Structured allergy history.
Table 1 Schedule of enrolment, interventions and assessments
Week
Study period
CloseoutEnrolment
Allocation Postallocation
V1V0 Follow-up questionnaires
0 4 8 12 16 20 24 24
Parent-completed
  Screening questionnaire ●
  Demographics and medical 
history
●
  POEM ● ● ● ● ● ● ● ●
  Other eczema symptoms† ● ● ● ● ● ● ●
  Other possible symptoms of 
food allergy
● ●
  Diet of child (and breastfeeding 
mother)
● ● ● ● ● ●
  Health service utilisation ● ● ● ● ● ●
  Out-of-pocket expenses/time 
off work
● ● ● ● ● ●
  ADQoL ● ● ●
  CHU-9D ● ● ●
  IDQoL ● ● ●
  Parental anxiety (GAD-7) ● ●
  Exit questionnaire ●
Researcher-administered
  UK diagnostic criteria for atopic 
dermatitis
●
  Other possible symptoms of 
food allergy
●
  Diet of child (and breastfeeding 
mother)
●
  EASI ● ●
  Structured allergy history ○
  Skin prick test (SPT) ○
  Oral food challenge (OFC) *
  Home dietary trial *
  EMR notes review ●
V0=baseline visit; V1=follow-up visit at 24 weeks.
●All participants; ○ Only participants in intervention group.
* only participants in intervention group with equivocal structured allergy history/SPT results.
† bother score, itch intensity, parent global assessment .
ADQoL, Atopic Dermatitis Quality of Life; CHU-9D, Children’s Health Utility 9D; EASI, Eczema Area Severity Index; EMR, electronic medical 
records; GAD-7, Generalised Anxiety Disorder 7; IDQoL, Infant Dermatitis Quality of Life; POEM, Patient Oriented Eczema Measure .
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 ► Results of SPT±OFC±home dietary trial.
data collection methods and retention
Baseline data will be collected by the CSO using paper 
case report forms (CRFs). Parents will be given the option 
of completing follow-up questionnaires either online or 
on paper. In recognition of participant’s time and to 
encourage retention in the study/data collection, parents 
of participants will be offered £10 vouchers at the base-
line and around the 24 weeks visit. We will also offer the 
child a small gift of about £5 in value.
blinding
It is not possible to blind participants, their families or 
treating clinicians to allocation. The research team will 
notify the appropriate GP surgery of the participant’s 
allocation and the outcome of any tests/investigations 
and food allergy diagnoses.
The CSO undertaking the baseline visit cannot be 
blinded, but all baseline data (including EASI) will be 
collected before randomisation. If possible, the follow-up 
visit will be done by a different CSO, who will be blinded 
to allocation. Parents will be asked not to disclose alloca-
tion to the CSO doing the follow-up visit. CSO blinding 
will be monitored by means of self-report.
Participant time line
Participants are in the study for 24 weeks, from the base-
line until the follow-up visit. Figure 1 provides an over-
view of the participants’ pathway through the study.
sample size
As this is a feasibility RCT, a formal sample size calcula-
tion is not appropriate. On a pragmatic basis, we have 
determined that 80 children (approximately 40 in each 
group) will be sufficient to provide estimates of recruit-
ment, retention, adherence and assessment of contami-
nation within GP surgeries and between groups. This is 
broadly in line with published ‘rules of thumb’.38 39
data management
Data will be entered onto the study database. The system 
will incorporate data entry and validation rules to reduce 
data entry errors, and management functions to facilitate 
auditing and data quality assurance.
statistical methods
The aim will be to determine the feasibility of undertaking 
the main trial and explore acceptability. We will report 
our findings following the pilot and feasibility exten-
sion of the Consolidated Standards of Reporting Trials 
(CONSORT) guidance (2010), including a CONSORT 
diagram, descriptive and summary statistics, along with 
all important harms or unintended effects in each group.
Descriptive statistics will be used to compare recruit-
ment, retention, adherence and contamination rates 
overall and between the two groups; and in the interven-
tion group, test results and adherence to dietary advice. 
Completion rates, average score and distributions (as 
appropriate) will be reported for the proposed outcomes 
in the main trial, for example, POEM and EASI.
Economic scoping
We will gather data on key costs and outcomes to assess 
the feasibility of carrying out a cost-effectiveness analysis 
from the primary perspective of the NHS and from a 
wider perspective including parental costs and time off 
work.
Data on healthcare contacts and prescribed medica-
tions will be extracted from EMRs. Additional health-
care contacts, information about parental out-of-pocket 
expenses and time off work will be collected using 
4-weekly parent-completed questionnaires. The overall 
level of missing data will be recorded and the pattern of 
missing data, by item, will be explored. Relevant unit costs 
will be identified and, once resource-use has been costed, 
we will identify which items are important cost drivers. 
The resources required for the intervention will be iden-
tified and the feasibility of costing these established.
NICE recommends the use of quality-adjusted life-years 
(QALYs) as the preferred outcome measure in economic 
evaluations, but it is unclear what the most appropriate 
underlying measure is for this population in estimating 
QALYs. Therefore, we will test feasibility and validity of 
using both condition-specific (ADQoL)32 and generic 
(CHU-9D)35 36 preference-based health-related quality 
of life measures in children (measured at baseline, 
8 weeks and 24 weeks) to estimate QALYs. The CHU-9D 
is currently validated for children aged 6 years and over, 
with pilot versions for those aged 5–7 years and additional 
guidance notes and validation questions for those under 
5 years. One key component of the economic work will be 
to determine the feasibility of using the CHU-9D in this 
preschool age group.
nested qualitative study
The aims of the qualitative study are to help interpret and 
explain the quantitative feasibility findings (including 
experience and acceptability of study processes/interven-
tions); and to generate new knowledge around the issues 
of food allergy, allergy tests and dietary modification in 
children with eczema, from the perspective of parents 
and GPs.
GPs at participating surgeries will be asked to complete 
a brief questionnaire and all parents and GPs will be asked 
whether they are willing to be contacted to take part in 
an interview. Semistructured qualitative interviews will be 
conducted with a sample of trial parents and GPs from 
participating surgeries, using topic guides developed 
based on study aims and input from the Trial Manage-
ment Group (TMG).
Parents will be selected purposively to ensure diversity 
in relevant characteristics: trial group (intervention or 
comparator) with oversampling of the intervention group; 
eczema severity according to POEM (mild/moderate 
[<17] vs severe [≥17]); socioeconomic status (assessed via 
postcode, using the Index of Multiple Deprivation Decile 
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[categories: high [8–10]/medium [5–7]/low [1–4]]);40 
for mothers, whether currently breast feeding; and length 
of time in the trial (shortly after baseline visit or OFC, 
or later in the trial). GPs will be purposively sampled 
to capture variation in GP surgery deprivation decile,40 
length of time in the trial, number of years’ experience as 
a GP and confidence in managing children with eczema 
(assessed via a single item scored: 1 [low] to 10 [high]). 
Sampling will stop when we have sufficient information 
power relevant to the study aims;41 we anticipate a total of 
20 parent and 10 GP interviews.
In addition, we will conduct brief telephone interviews 
with 5–8 parents who are ineligible to participate, decline 
to take part, or withdraw during the trial but indicate that 
they are willing to discuss reasons why. This information 
may provide valuable data to inform the design of a future 
definitive trial.
Interviews will be conducted by an experienced qual-
itative researcher, either by telephone or face to face, 
depending on the preference of the interviewee, audio-re-
corded (with permission) and transcribed verbatim. 
All interviewees will receive an information sheet and 
consent form to read in advance of the interview. Written 
informed consent will be taken prior to face-to-face inter-
views, and verbal consent will be taken for telephone 
interviews.
Data analysis of interview transcripts will take place 
alongside data collection and inform further data 
collection. We will conduct a thematic analysis, using 
both inductive and deductive coding (informed by the 
Common Sense model).42
Monitoring, safety and audit
Because this is a low-risk feasibility trial, the trial is over-
seen by a joint Trial Steering/Data Monitoring Committee 
(TS/DM-C) which comprises four independent members: 
a chairperson, a biostatistician, a clinician and a patient 
representative (parent of child with eczema). Their role 
will be to provide overall supervision of the trial on behalf 
of the funder, with a focus on progress of the trial, adher-
ence to the protocol, patient safety and consideration of 
new information.
Adverse events will be collected in the CRFs and by 
parent/clinician report and reported to the TMG and 
TS/DM-C. Possible serious adverse events include:
 ► Severe localised reaction (redness, swelling, itch) to 
one or more SPTs necessitating medication and/or 
hospitalisation.
 ► Anaphylactic reaction (generalised flushing of the 
skin, hives, swelling of throat and mouth, difficulty in 
swallowing or speaking, tachycardia, severe asthma, 
abdominal pain and/or nausea and vomiting, hypo-
tension and/or collapse and unconsciousness) 
requiring medication±hospitalisation (SPTs or 
OFC).
The sponsor organisation is the University of Bristol.
PrEgrAnt APPlICAtIon survEy
An online survey of parents of children with eczema 
informed the study design. It was promoted via social 
media and partner eczema and allergy websites between 
10 October 2016 and 27 October 2016. We received 152 
responses, 97% (145/150) female with a mean age of 38.8 
years. The median number of children with eczema was 
1 (IQR 1, 2) and the mean POEM score (for the worst-af-
fected child, with more than one child with eczema) was 
11.7 (SD 7.6). Seventy-four per cent (108/146) had one 
or more food allergies, the most common being peanut, 
egg and cow’s milk; 71.3% (77/108) had received allergy 
tests and had been given advice by a healthcare profes-
sional and 17.6% (19/108) based their report on their 
observation of symptoms/reaction alone.
Participants were asked 'In a study that compares the 
effect of doing allergy tests or giving advice on avoiding 
certain foods in children, what would be the single most 
important thing that this kind of study could tell you 
about?’ Overall, 37% (56/151) chose ‘Reduce the risk 
of a sudden or severe allergic reaction’. However, among 
those children without a reported food allergy (the group 
of interest in this study), 44% (16/36) chose ‘Reduce 
day-to-day severity of eczema’. Consequently, we included 
eczema severity as a key clinical outcome.
Regarding the then proposed study, 96% (144/150) 
said they would be willing for their child to have an allergy 
test, with 67.1% (100/149) identifying skin prick as their 
‘first choice’ option for testing for allergy and 54.3% 
(82/151) saying a blood test was an acceptable ‘second 
choice’. Other participants said they would refuse (4.0% 
skin prick, 8.5% blood test) or did not know (2.0% skin 
prick, 2.6% blood test). Further information about the 
limitations of both types of tests (risk of false reassurance 
or worry) did not change the opinion of the majority 
(72.5%, 108/149) of respondents; 56.9% (74/130) said 
that based on the clinical history and allergy test, they 
would be willing to avoid that food for at least 24 months. 
These findings provided reassurance as to the accept-
ability of the intervention, which includes SPTs and the 
possibility of having to exclude foods for at least several 
months.
PublIC And PAtIEnt InvolvEMEnt
The James Lind Alliance Eczema Priority Setting Part-
nership (2013) identified the following questions: ‘What 
role might food allergy tests play in treating eczema?’ 
and ‘What is the role of (exclusion) diets in treating 
eczema?',43 which a follow-on definitive trial could begin 
to address.
Two mothers of children with eczema (Catherine Gray 
and Jo McMeechan) are members of the TMG and regu-
larly attend the meetings. They have commented on the 
research proposal and study paperwork, and their sugges-
tions around nomenclature and reducing data burden on 
participants have been incorporated. A lay member also 
sits on TS/DM-C.
 o
n
 28 M
ay 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-028428 on 9 May 2019. Downloaded from 
8 Ridd MJ, et al. BMJ Open 2019;9:e028428. doi:10.1136/bmjopen-2018-028428
Open access 
We have established and met with a wider PPI advisory 
group. It first met towards the beginning of the research 
to discuss data burden and the design of patient-facing 
materials. At a subsequent meeting, study progress and 
challenges were discussed. One more meeting is planned 
towards the end of the study, to inform write-up and 
dissemination of findings.
EthICs And dIssEMInAtIon
Protocol amendments
Any amendments to the protocol will be reported accord-
ingly to the regulatory bodies, with a full copy of the 
current protocol available for download from the study 
website. Amendments to date are listed in online supple-
mentary appendix 1.
Consent or assent
Written consent for taking part in the trial will be received 
by a CSO from the parent or guardian of the participant at 
their baseline appointment, which takes place in a partici-
pating GP practice. Consent is also sought to contact partic-
ipants regarding possible interview in the nested qualitative 
study; and for the reuse of the anonymised data in future 
research for purposes not related to this study, including as 
publicly available ‘open data’ (see online supplementary 
appendix 2). Consent for OFCs is received by the hospital 
nurse undertaking the procedure.
Confidentiality and access to data
The database and randomisation system will protect patient 
information in line with the data protection legislation. Trial 
staff will ensure that participants’ anonymity is maintained 
through protective and secure handling and storage of 
patient information at the trial centre.
The chief investigator will have access to and act as 
custodian of the full data set, which will be made avail-
able to the TS/DM-C if requested to verify the validity of 
the findings.
Ancillary and post-trial care
Participants requiring follow-up beyond their 6 months in 
the study will be referred by their GP to their local allergy 
clinic.
data sharing
Study progress, outputs and a summary of findings will be 
made available via a study website and Twitter account; 
and summaries distributed to participating families and 
GP surgeries. 
No later than 3 years after the completion of the study, 
we will make available a completely deidentified data set 
to an appropriate data archive for sharing purposes.
dIsCussIon
There are wide variations in provision of allergy testing 
for children with eczema. Parental concern and clinician 
uncertainty about the role of food allergy in eczema has 
been highlighted as a barrier to effective treatment.44 Up 
to 70% of parents make significant modifications to their 
child’s diet, often without professional advice,45 even if 
the child has only mild eczema. Many parents turn to the 
internet for advice,12 46 or purchase self-test allergy kits 
which are not validated and not recommended.16
It is uncommon for allergy tests to be undertaken in 
primary care but in principle, allergy testing (in the 
form of SPTs) and advice could be routinely delivered 
in primary care, but evidence is required to demon-
strate both the feasibility and value of doing so. An RCT 
is needed to determine the clinical effectiveness and 
cost effectiveness of food allergy testing and advice in 
primary care, on severity of eczema in children. There are 
potentially significant benefits for the NHS of improving 
long-term eczema management, avoiding serious allergic 
reactions, and targeting child nutrition. This study will 
provide important data to first, determine the feasibility 
of a large, definitive trial; and second, to inform its design.
The full/most up-to-date version of the protocol is avail-
able to download from the study website. The first partici-
pant was randomised in September 2018 and recruitment 
is ongoing. Follow-up is expected to be complete by 
September 2019. We expect to report in early 2020.
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